A Study to Evaluate the Safety and Effectiveness of a Silicone Hydrogel Custom Contact Lens When Compared to Alden Optical HP Sphere Lens
A Study to Evaluate the Safety and Effectiveness of a Silicone Hydrogel Custom Contact Lens
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94112
- Bausch site 1
-
-
Colorado
-
Denver, Colorado, United States, 80246
- Bausch Site 2
-
-
Florida
-
Sarasota, Florida, United States, 34232
- Bausch Site 3
-
-
Kansas
-
Pittsburg, Kansas, United States, 66762
- Bausch Site 4
-
-
Missouri
-
Warrensburg, Missouri, United States, 64093
- Bausch Site 5
-
-
New York
-
Vestal, New York, United States, 13850
- Bausch Site 6
-
-
Wisconsin
-
New Berlin, Wisconsin, United States, 53151
- Bausch Site 7
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participants must be able to read, understand, and provide written informed consent on the institutional review board (IRB)-approved informed consent form (ICF) and provide authorization as appropriate for local privacy regulations.
- Participants must have clear central corneas and be free of any anterior segment disorders in each eye.
- Participants must be myopic, require contact lens correction from -1.00 diopter (D) to -6.00 D, and wear contact lenses in each eye.
- Participants must be correctable through spherocylindrical refraction to 47 letters (0.0 logMAR) or better (distance, high-contrast) in each eye.
- Participants must be able and willing to comply with all treatment and follow-up/study procedures.
- Participants must be adapted soft contact lens wearers and agree to wear their study lenses on a daily wear basis for approximately 3 months.
Exclusion Criteria:
- Participants participating in any drug or device clinical investigation within 2 weeks prior to entry into this study and/or during the period of study participation.
- Participants who are women of childbearing potential (those who are not surgically sterilized or postmenopausal), who are currently pregnant, plan to become pregnant during the study, or are breastfeeding.
- Participants who have worn gas permeable lenses in either eye within the last 30 days or who have worn polymethylmethacrylate lenses in either eye within the last 3 months.
- Participants with any systemic disease currently affecting ocular health or which, in the Investigator's opinion, may have an effect on ocular health in either eye during the course of the study.
- Participants using any systemic or topical medications that will, in the Investigator's opinion, affect ocular physiology or lens performance.
- Participants with an active ocular disease in either eye or who are using any ocular medication.
- Participants who currently wear monovision, multifocal, or toric contact lenses in either eye.
- Participants with an ocular astigmatism >1.00 D in either eye.
- Participants with anisometropia (spherical equivalent) >2.00 D.
- Participants with any Grade ≥2 finding in either eye during the slit lamp examination. Participants with corneal infiltrates in either eye, of any grade, are not eligible to participate in this study.
- Participants with any "present" finding during the slit lamp examination in either eye that, in the Investigator's judgment, interferes with contact lens wear.
- Participants with any scar or neovascularization within the central 6 millimeters (mm) of the cornea in either eye. Note: participants with minor peripheral corneal scarring (that does not extend into the central area), that in the Investigator's judgment, does not interfere with contact lens wear, are eligible to participate in this study.
- Participants who are aphakic in either eye.
- Participants who are amblyopic in either eye.
- Participants who have had any corneal surgery (for example, refractive surgery) in either eye.
- Participants who are allergic to any component in the study care products.
Participants who meet any of the following criteria:
- The participant is an employee of the investigative site.
- The participant, or a member of the participant's household, is an ophthalmologist, an optometrist, an optician, or an ophthalmic assistant/technician.
- The participant, or a member of the participant's household, is an employee of a manufacturer of contact lenses or contact lens care products (for example, Alcon, Bausch + Lomb, Ciba Vision, CooperVision, or Johnson & Johnson).
- The participant, or a member of the participant's household, is an employee of a market research firm.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Custom Samfilcon B Contact Lenses
Participants will wear Bausch + Lomb investigational custom samfilcon B contact lenses daily for 3 months.
Participants will be provided with ReNu MultiPlus Lubricating and Rewetting Drops for use as needed during the study.
Participants will store their worn study lenses in a lens case filled with Biotrue multi-purpose solution (MPS).
|
Contact lens
For use as needed during the study.
Other Names:
For daily rinsing, cleaning, disinfecting, and storing their lenses in lens cases during the study.
Other Names:
|
|
Placebo Comparator: Alden Optical HP Sphere contact lenses
Participants will wear Alden Optical HP Sphere contact lenses daily for 3 months.
Participants will be provided with ReNu MultiPlus Lubricating and Rewetting Drops for use as needed during the study.
Participants will store worn study lenses in a lens case filled with Biotrue MPS.
|
For use as needed during the study.
Other Names:
For daily rinsing, cleaning, disinfecting, and storing their lenses in lens cases during the study.
Other Names:
Hioxifilcon D, 54% water, Alden Optical HP Sphere lens
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean Distance High-contrast logMAR Lens VA
Time Frame: Month 3
|
Monocular distance high-contrast logarithm of the minimum angle of resolution (logMAR) lens visual acuity (VA) will be assessed at Week 1, Month 1, Month 2, and Month.
For each eye LogMAR will be averaged at Week 1, Month 1, Month 2, and Month 3 visits, resulting in 1 value of "All Study" logMAR lens VA per eye.
|
Month 3
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion Of Eyes With Grade >2 Slit Lamp Findings
Time Frame: Month 3
|
Graded slit lamp findings will be assessed at Month 3. Each eye will be classified with respect to having 1 or more observations with Grade >2 (Yes, No) at any visit. Criteria of each grade: 0=None, 1= Trace, 2= Mild, 3=Moderate, 4= Severe. Higher grades are worse outcomes. |
Month 3
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Johnson Varughese, Bausch & Lomb Incorporated
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- 886
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.